Biomarkers in Breast Cancer [electronic resource] : Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect / edited by Giampietro Gasparini, Daniel F. Hayes.
| Call Number | 614.5999 |
| Title | Biomarkers in Breast Cancer Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect / edited by Giampietro Gasparini, Daniel F. Hayes. |
| Physical Description | XII, 342 p. 22 illus. online resource. |
| Series | Cancer Drug Discovery and Development |
| Contents | General Topics -- Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems -- Analytical Aspects of Biomarker Immunoassays in Cancer Research -- Tissue Microarrays -- Assays for Gene Expression and Post-Translational Protein Abnormalities -- Gene Expression Profiling with DNA Microarrays -- Assays for DNA Abnormalities -- Assays for Gene Amplification -- Tissue Predictive Biomakers -- Cell Kinetics -- Urokinase-Type Plasminogen Activator and PAI-1 -- Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer -- erb-B2 as a Therapeutic Target -- The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer -- p53 as a Prognostic and Predictive Indicator -- Predictive Biomarkers in Body Fluids -- Occult Metastatic Cells in Breast Cancer Patients -- Circulating HER2/neu -- Circulating Vascular Endothelial Growth Factor -- Detection of Early Tumor Dissemination in Patients With Breast Cancer -- Future Directions -- New Technologies/New Markers/New Challenges. |
| Summary | It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy. |
| Added Author | Gasparini, Giampietro. editor. Hayes, Daniel F. editor. SpringerLink (Online service) |
| Subject | MEDICINE. CANCER RESEARCH. Biomedicine. Cancer Research. |
| Multimedia |
-
Libraries with this item
-
950 BiomedicalandLifeSciences(Springer-11642)
Total Ratings:
0
04404nam a22004695i 4500
001
vtls001568509
003
VRT
005
20170831183600.0
007
cr nn 008mamaa
008
170831s2006 xxu| s |||| 0|eng d
020
$a 9781592599158 $9 978-1-59259-915-8
024
7
$a 10.1385/159259915X $2 doi
035
$a (DE-He213)978-1-59259-915-8
039
9
$y 201708311836 $z santha
050
4
$a RC261-271
072
7
$a MJCL $2 bicssc
072
7
$a MED062000 $2 bisacsh
082
0
4
$a 614.5999 $2 23
245
1
0
$a Biomarkers in Breast Cancer $h [electronic resource] : $b Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect / $c edited by Giampietro Gasparini, Daniel F. Hayes.
264
1
$a Totowa, NJ : $b Humana Press, $c 2006.
300
$a XII, 342 p. 22 illus. $b online resource.
336
$a text $b txt $2 rdacontent
337
$a computer $b c $2 rdamedia
338
$a online resource $b cr $2 rdacarrier
347
$a text file $b PDF $2 rda
490
1
$a Cancer Drug Discovery and Development
505
0
$a General Topics -- Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems -- Analytical Aspects of Biomarker Immunoassays in Cancer Research -- Tissue Microarrays -- Assays for Gene Expression and Post-Translational Protein Abnormalities -- Gene Expression Profiling with DNA Microarrays -- Assays for DNA Abnormalities -- Assays for Gene Amplification -- Tissue Predictive Biomakers -- Cell Kinetics -- Urokinase-Type Plasminogen Activator and PAI-1 -- Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer -- erb-B2 as a Therapeutic Target -- The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer -- p53 as a Prognostic and Predictive Indicator -- Predictive Biomarkers in Body Fluids -- Occult Metastatic Cells in Breast Cancer Patients -- Circulating HER2/neu -- Circulating Vascular Endothelial Growth Factor -- Detection of Early Tumor Dissemination in Patients With Breast Cancer -- Future Directions -- New Technologies/New Markers/New Challenges.
520
$a It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy.
650
0
$a MEDICINE.
650
0
$a CANCER RESEARCH.
650
1
4
$a Biomedicine.
650
2
4
$a Cancer Research.
700
1
$a Gasparini, Giampietro. $e editor.
700
1
$a Hayes, Daniel F. $e editor.
710
2
$a SpringerLink (Online service)
773
0
$t Springer eBooks
776
0
8
$i Printed edition: $z 9781588292278
830
0
$a Cancer Drug Discovery and Development
856
4
0
$u http://dx.doi.org/10.1385/159259915X
912
$a ZDB-2-SBL
950
$a Biomedical and Life Sciences (Springer-11642)
999
$a VIRTUA
No Reviews to Display
| Summary | It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy. |
| Contents | General Topics -- Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems -- Analytical Aspects of Biomarker Immunoassays in Cancer Research -- Tissue Microarrays -- Assays for Gene Expression and Post-Translational Protein Abnormalities -- Gene Expression Profiling with DNA Microarrays -- Assays for DNA Abnormalities -- Assays for Gene Amplification -- Tissue Predictive Biomakers -- Cell Kinetics -- Urokinase-Type Plasminogen Activator and PAI-1 -- Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer -- erb-B2 as a Therapeutic Target -- The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer -- p53 as a Prognostic and Predictive Indicator -- Predictive Biomarkers in Body Fluids -- Occult Metastatic Cells in Breast Cancer Patients -- Circulating HER2/neu -- Circulating Vascular Endothelial Growth Factor -- Detection of Early Tumor Dissemination in Patients With Breast Cancer -- Future Directions -- New Technologies/New Markers/New Challenges. |
| Subject | MEDICINE. CANCER RESEARCH. Biomedicine. Cancer Research. |
| Multimedia |